Skip to content

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

About
Science
- Overview
- Publications
Pipeline
Investors
Careers
Contact

Press Releases

Choose Year
Search Press Releases

Found 83 Results

May 10, 2023

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

April 5, 2023

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

March 22, 2023

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

March 20, 2023

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22,2023

January 4, 2023

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

November 14, 2022

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 10, 2022

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

October 6, 2022

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

September 26, 2022

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

August 11, 2022

Surrozen Reports Second Quarter 2022 Financial Results

«...2 345 6...»

IR Contact

Email: investorinfo@surrozen.com

Email Alerts Sign-Up

Email

Unsubscribe

Loading...

Company

About
Management
Board of Directors
Scientific Advisors
Contact
Careers

Science

Science
Pipeline
Publications

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Copyright © 2026 Surrozen. All Rights Reserved

FCOI Policy
Accessibility

Scroll to Top